FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:NRXN2-APOE (FusionGDB2 ID:60006)

Fusion Gene Summary for NRXN2-APOE

check button Fusion gene summary
Fusion gene informationFusion gene name: NRXN2-APOE
Fusion gene ID: 60006
HgeneTgene
Gene symbol

NRXN2

APOE

Gene ID

9379

348

Gene nameneurexin 2apolipoprotein E
Synonyms-AD2|APO-E|ApoE4|LDLCQ5|LPG
Cytomap

11q13.1

19q13.32

Type of geneprotein-codingprotein-coding
Descriptionneurexin-2-betaneurexin IIapolipoprotein Eapolipoprotein E3
Modification date2020031320200329
UniProtAcc

Q9P2S2

P02649

Ensembl transtripts involved in fusion geneENST00000377559, ENST00000265459, 
ENST00000301894, ENST00000377551, 
ENST00000409571, ENST00000496291, 
ENST00000252486, 
Fusion gene scores* DoF score4 X 4 X 3=485 X 5 X 5=125
# samples 45
** MAII scorelog2(4/48*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(5/125*10)=-1.32192809488736
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: NRXN2 [Title/Abstract] AND APOE [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointNRXN2(64391039)-APOE(45411017), # samples:5
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneAPOE

GO:0001937

negative regulation of endothelial cell proliferation

9685360

TgeneAPOE

GO:0006641

triglyceride metabolic process

9649566

TgeneAPOE

GO:0006898

receptor-mediated endocytosis

1917954

TgeneAPOE

GO:0007186

G protein-coupled receptor signaling pathway

16443932

TgeneAPOE

GO:0007263

nitric oxide mediated signal transduction

8995232

TgeneAPOE

GO:0008203

cholesterol metabolic process

9649566

TgeneAPOE

GO:0010544

negative regulation of platelet activation

8995232

TgeneAPOE

GO:0010873

positive regulation of cholesterol esterification

15654758

TgeneAPOE

GO:0010875

positive regulation of cholesterol efflux

12042316|14754908

TgeneAPOE

GO:0010976

positive regulation of neuron projection development

7592957|23845000

TgeneAPOE

GO:0010977

negative regulation of neuron projection development

7592957

TgeneAPOE

GO:0015909

long-chain fatty acid transport

24345162

TgeneAPOE

GO:0017038

protein import

24446231

TgeneAPOE

GO:0019934

cGMP-mediated signaling

8995232

TgeneAPOE

GO:0030195

negative regulation of blood coagulation

8995232

TgeneAPOE

GO:0031175

neuron projection development

8939961

TgeneAPOE

GO:0032489

regulation of Cdc42 protein signal transduction

16443932

TgeneAPOE

GO:0032805

positive regulation of low-density lipoprotein particle receptor catabolic process

15950758

TgeneAPOE

GO:0033344

cholesterol efflux

11162594|16443932|23620513

TgeneAPOE

GO:0033700

phospholipid efflux

11162594

TgeneAPOE

GO:0034372

very-low-density lipoprotein particle remodeling

15654758

TgeneAPOE

GO:0034380

high-density lipoprotein particle assembly

14754908|17305370

TgeneAPOE

GO:0034382

chylomicron remnant clearance

1911868

TgeneAPOE

GO:0034384

high-density lipoprotein particle clearance

210175

TgeneAPOE

GO:0034447

very-low-density lipoprotein particle clearance

1917954|2762297

TgeneAPOE

GO:0042158

lipoprotein biosynthetic process

23620513

TgeneAPOE

GO:0042632

cholesterol homeostasis

9649566

TgeneAPOE

GO:0042982

amyloid precursor protein metabolic process

21593558

TgeneAPOE

GO:0043254

regulation of protein complex assembly

25207746

TgeneAPOE

GO:0043407

negative regulation of MAP kinase activity

9685360

TgeneAPOE

GO:0043537

negative regulation of blood vessel endothelial cell migration

9685360

TgeneAPOE

GO:0043691

reverse cholesterol transport

8127890

TgeneAPOE

GO:0045541

negative regulation of cholesterol biosynthetic process

1917954

TgeneAPOE

GO:0045807

positive regulation of endocytosis

7683668|8300609

TgeneAPOE

GO:0046889

positive regulation of lipid biosynthetic process

12042316

TgeneAPOE

GO:0051000

positive regulation of nitric-oxide synthase activity

8995232

TgeneAPOE

GO:0051044

positive regulation of membrane protein ectodomain proteolysis

15950758

TgeneAPOE

GO:0055089

fatty acid homeostasis

24345162

TgeneAPOE

GO:0060999

positive regulation of dendritic spine development

24328732

TgeneAPOE

GO:0071831

intermediate-density lipoprotein particle clearance

1917954

TgeneAPOE

GO:0090090

negative regulation of canonical Wnt signaling pathway

16805831

TgeneAPOE

GO:0097113

AMPA glutamate receptor clustering

24328732

TgeneAPOE

GO:0097114

NMDA glutamate receptor clustering

24328732

TgeneAPOE

GO:1900221

regulation of amyloid-beta clearance

24446231

TgeneAPOE

GO:1900272

negative regulation of long-term synaptic potentiation

16273551

TgeneAPOE

GO:1902430

negative regulation of amyloid-beta formation

24154541

TgeneAPOE

GO:1902952

positive regulation of dendritic spine maintenance

24328732

TgeneAPOE

GO:1902991

regulation of amyloid precursor protein catabolic process

28164773

TgeneAPOE

GO:1902995

positive regulation of phospholipid efflux

12042316

TgeneAPOE

GO:1903002

positive regulation of lipid transport across blood brain barrier

24345162

TgeneAPOE

GO:1905855

positive regulation of heparan sulfate binding

7683668

TgeneAPOE

GO:1905860

positive regulation of heparan sulfate proteoglycan binding

8300609

TgeneAPOE

GO:1905890

regulation of cellular response to very-low-density lipoprotein particle stimulus

7592957

TgeneAPOE

GO:1905906

regulation of amyloid fibril formation

25207746


check buttonFusion gene breakpoints across NRXN2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check buttonFusion gene breakpoints across APOE (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check button Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerDB4LGGTCGA-HT-7681NRXN2chr11

64391039

-APOEchr19

45411017

+
ChimerDB4LGGTCGA-HT-A616NRXN2chr11

64391039

-APOEchr19

45411017

+
ChimerDB4LGGTCGA-FG-A4MYNRXN2chr11

64391039

-APOEchr19

45411017

+
ChimerDB4LGGTCGA-DB-A75ONRXN2chr11

64391039

-APOEchr19

45411017

+
ChimerDB4SKCMTCGA-EB-A3XF-01ANRXN2chr11

64391039

-APOEchr19

45411017

+


Top

Fusion Gene ORF analysis for NRXN2-APOE

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
intron-3CDSENST00000377559ENST00000252486NRXN2chr11

64391039

-APOEchr19

45411017

+
intron-3CDSENST00000265459ENST00000252486NRXN2chr11

64391039

-APOEchr19

45411017

+
intron-3CDSENST00000301894ENST00000252486NRXN2chr11

64391039

-APOEchr19

45411017

+
intron-3CDSENST00000377551ENST00000252486NRXN2chr11

64391039

-APOEchr19

45411017

+
intron-3CDSENST00000409571ENST00000252486NRXN2chr11

64391039

-APOEchr19

45411017

+
intron-3CDSENST00000496291ENST00000252486NRXN2chr11

64391039

-APOEchr19

45411017

+

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score

Top

Fusion Genomic Features for NRXN2-APOE


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for NRXN2-APOE


check button Go to

FGviewer for the breakpoints of :-:

.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
NRXN2

Q9P2S2

APOE

P02649

FUNCTION: Neuronal cell surface protein that may be involved in cell recognition and cell adhesion. May mediate intracellular signaling.FUNCTION: APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:6860692, PubMed:1911868, PubMed:14754908). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:6860692, PubMed:2762297, PubMed:1911868, PubMed:1917954, PubMed:9395455, PubMed:14754908, PubMed:23620513). Apoliproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma (PubMed:6860692, PubMed:2762297, PubMed:9395455). As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL) (PubMed:6860692, PubMed:1911868). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles (PubMed:2762297, PubMed:1917954, PubMed:7768901, PubMed:8939961, PubMed:12950167, PubMed:20030366, PubMed:2063194, PubMed:8756331, PubMed:20303980, PubMed:1530612, PubMed:7635945). Finally, APOE has also a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells (PubMed:9395455, PubMed:9488694, PubMed:23676495, PubMed:7635945). A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes (PubMed:1911868, PubMed:1917954, PubMed:9395455, PubMed:23676495, PubMed:29516132). APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues (PubMed:2762297, PubMed:29516132). By participating in the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis (PubMed:2762297, PubMed:1917954, PubMed:29516132). APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis (PubMed:9395455, PubMed:14754908, PubMed:23620513). First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues (PubMed:14754908, PubMed:23620513). Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes (PubMed:9395455). APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting (PubMed:8939961, PubMed:25173806). APOE in also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells (By similarity). APOE, may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP (PubMed:28111074). {ECO:0000250|UniProtKB:P08226, ECO:0000269|PubMed:12950167, ECO:0000269|PubMed:14754908, ECO:0000269|PubMed:1530612, ECO:0000269|PubMed:1911868, ECO:0000269|PubMed:1917954, ECO:0000269|PubMed:20030366, ECO:0000269|PubMed:20303980, ECO:0000269|PubMed:2063194, ECO:0000269|PubMed:23620513, ECO:0000269|PubMed:23676495, ECO:0000269|PubMed:2762297, ECO:0000269|PubMed:28111074, ECO:0000269|PubMed:6860692, ECO:0000269|PubMed:7635945, ECO:0000269|PubMed:7768901, ECO:0000269|PubMed:8756331, ECO:0000269|PubMed:8939961, ECO:0000269|PubMed:9395455, ECO:0000269|PubMed:9488694, ECO:0000303|PubMed:25173806, ECO:0000303|PubMed:29516132}.; FUNCTION: (Microbial infection) Through its interaction with HCV envelope glycoprotein E2, participates in the attachment of HCV to HSPGs and other receptors (LDLr, VLDLr, and SR-B1) on the cell surface and to the assembly, maturation and infectivity of HCV viral particles (PubMed:25122793, PubMed:29695434). This interaction is probably promoted via the up-regulation of cellular autophagy by the virus (PubMed:29695434). {ECO:0000269|PubMed:25122793, ECO:0000269|PubMed:29695434}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note


Top

Fusion Gene Sequence for NRXN2-APOE


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

Top

Fusion Gene PPI Analysis for NRXN2-APOE


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for NRXN2-APOE


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
TgeneAPOEP02649DB14548Zinc sulfate, unspecified formAntagonistSmall moleculeApproved|Experimental
TgeneAPOEP02649DB01593ZincSmall moleculeApproved|Investigational
TgeneAPOEP02649DB09130CopperSmall moleculeApproved|Investigational
TgeneAPOEP02649DB14487Zinc acetateSmall moleculeApproved|Investigational
TgeneAPOEP02649DB14533Zinc chlorideAntagonistSmall moleculeApproved|Investigational

Top

Related Diseases for NRXN2-APOE


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneNRXN2C1510586Autism Spectrum Disorders2CTD_human;GENOMICS_ENGLAND
HgeneNRXN2C0036341Schizophrenia1PSYGENET
HgeneNRXN2C3714756Intellectual Disability1GENOMICS_ENGLAND
TgeneAPOEC0004153Atherosclerosis29CTD_human
TgeneAPOEC1563937Atherogenesis29CTD_human
TgeneAPOEC0020479Hyperlipoproteinemia Type III16CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
TgeneAPOEC0015697Arterial Fatty Streak11CTD_human
TgeneAPOEC0264956Atheroma11CTD_human
TgeneAPOEC1863051ALZHEIMER DISEASE 211CTD_human;GENOMICS_ENGLAND;UNIPROT
TgeneAPOEC2936350Plaque, Atherosclerotic11CTD_human
TgeneAPOEC2936351Fibroatheroma11CTD_human
TgeneAPOEC0002395Alzheimer's Disease9CTD_human
TgeneAPOEC0011265Presenile dementia9CTD_human
TgeneAPOEC0276496Familial Alzheimer Disease (FAD)9CTD_human
TgeneAPOEC0494463Alzheimer Disease, Late Onset9CTD_human
TgeneAPOEC0546126Acute Confusional Senile Dementia9CTD_human
TgeneAPOEC0750900Alzheimer's Disease, Focal Onset9CTD_human
TgeneAPOEC0750901Alzheimer Disease, Early Onset9CTD_human
TgeneAPOEC2673196LIPOPROTEIN GLOMERULOPATHY6CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
TgeneAPOEC0011206Delirium5PSYGENET
TgeneAPOEC0001973Alcoholic Intoxication, Chronic4PSYGENET
TgeneAPOEC0020443Hypercholesterolemia4CTD_human
TgeneAPOEC0020473Hyperlipidemia4CTD_human
TgeneAPOEC0745103Hyperlipoproteinemia Type IIa4CTD_human;UNIPROT
TgeneAPOEC1706412Lipidemias4CTD_human
TgeneAPOEC0003850Arteriosclerosis2CTD_human
TgeneAPOEC0005586Bipolar Disorder2PSYGENET
TgeneAPOEC0020538Hypertensive disease2CTD_human
TgeneAPOEC0024121Lung Neoplasms2CTD_human
TgeneAPOEC0036489Sea-Blue Histiocyte Syndrome2CTD_human;GENOMICS_ENGLAND;ORPHANET
TgeneAPOEC0242379Malignant neoplasm of lung2CTD_human
TgeneAPOEC0000786Spontaneous abortion1CTD_human
TgeneAPOEC0000822Abortion, Tubal1CTD_human
TgeneAPOEC0001418Adenocarcinoma1CTD_human
TgeneAPOEC0002726Amyloidosis1CTD_human
TgeneAPOEC0007222Cardiovascular Diseases1CTD_human
TgeneAPOEC0007273Carotid Artery Diseases1CTD_human
TgeneAPOEC0007282Carotid Stenosis1CTD_human
TgeneAPOEC0009241Cognition Disorders1CTD_human
TgeneAPOEC0010068Coronary heart disease1CTD_human
TgeneAPOEC0013990Pathological accumulation of air in tissues1CTD_human
TgeneAPOEC0019193Hepatitis, Toxic1CTD_human
TgeneAPOEC0019202Hepatolenticular Degeneration1CTD_human
TgeneAPOEC0020445Hypercholesterolemia, Familial1CTD_human
TgeneAPOEC0022333Jacksonian Seizure1CTD_human
TgeneAPOEC0025427Mercury Poisoning1CTD_human
TgeneAPOEC0026769Multiple Sclerosis1CTD_human
TgeneAPOEC0027051Myocardial Infarction1CTD_human
TgeneAPOEC0027746Nerve Degeneration1CTD_human
TgeneAPOEC0028754Obesity1CTD_human
TgeneAPOEC0030246Pustulosis of Palms and Soles1CTD_human
TgeneAPOEC0033687Proteinuria1CTD_human
TgeneAPOEC0033860Psoriasis1CTD_human
TgeneAPOEC0035078Kidney Failure1CTD_human
TgeneAPOEC0036341Schizophrenia1CTD_human
TgeneAPOEC0036572Seizures1CTD_human
TgeneAPOEC0038002Splenomegaly1CTD_human
TgeneAPOEC0085220Cerebral Amyloid Angiopathy1CTD_human
TgeneAPOEC0085762Alcohol abuse1PSYGENET
TgeneAPOEC0149958Complex partial seizures1CTD_human
TgeneAPOEC0205641Adenocarcinoma, Basal Cell1CTD_human
TgeneAPOEC0205642Adenocarcinoma, Oxyphilic1CTD_human
TgeneAPOEC0205643Carcinoma, Cribriform1CTD_human
TgeneAPOEC0205644Carcinoma, Granular Cell1CTD_human
TgeneAPOEC0205645Adenocarcinoma, Tubular1CTD_human
TgeneAPOEC0234533Generalized seizures1CTD_human
TgeneAPOEC0234535Clonic Seizures1CTD_human
TgeneAPOEC0235874Disease Exacerbation1CTD_human
TgeneAPOEC0242339Dyslipidemias1CTD_human
TgeneAPOEC0242383Age related macular degeneration1CTD_human
TgeneAPOEC0270824Visual seizure1CTD_human
TgeneAPOEC0270844Tonic Seizures1CTD_human
TgeneAPOEC0270846Epileptic drop attack1CTD_human
TgeneAPOEC0338582Sporadic Cerebral Amyloid Angiopathy1CTD_human
TgeneAPOEC0340569Internal Carotid Artery Stenosis1CTD_human
TgeneAPOEC0393664Multiple Sclerosis, Acute Relapsing1CTD_human
TgeneAPOEC0422850Seizures, Somatosensory1CTD_human
TgeneAPOEC0422852Seizures, Auditory1CTD_human
TgeneAPOEC0422853Olfactory seizure1CTD_human
TgeneAPOEC0422854Gustatory seizure1CTD_human
TgeneAPOEC0422855Vertiginous seizure1CTD_human
TgeneAPOEC0494475Tonic - clonic seizures1CTD_human
TgeneAPOEC0577631Carotid Atherosclerosis1CTD_human
TgeneAPOEC0598784Dyslipoproteinemias1CTD_human
TgeneAPOEC0600178External Carotid Artery Diseases1CTD_human
TgeneAPOEC0750986Internal Carotid Artery Diseases1CTD_human
TgeneAPOEC0750987Arterial Diseases, Common Carotid1CTD_human
TgeneAPOEC0751056Non-epileptic convulsion1CTD_human
TgeneAPOEC0751110Single Seizure1CTD_human
TgeneAPOEC0751123Atonic Absence Seizures1CTD_human
TgeneAPOEC0751324Multiple Sclerosis, Acute Fulminating1CTD_human
TgeneAPOEC0751494Convulsive Seizures1CTD_human
TgeneAPOEC0751495Seizures, Focal1CTD_human
TgeneAPOEC0751496Seizures, Sensory1CTD_human
TgeneAPOEC0751633Carotid Artery Plaque1CTD_human
TgeneAPOEC0751634Carotid Ulcer1CTD_human
TgeneAPOEC0751635Common Carotid Artery Stenosis1CTD_human
TgeneAPOEC0751636External Carotid Artery Stenosis1CTD_human
TgeneAPOEC0751967Multiple Sclerosis, Relapsing-Remitting1CTD_human
TgeneAPOEC0860207Drug-Induced Liver Disease1CTD_human
TgeneAPOEC1262760Hepatitis, Drug-Induced1CTD_human
TgeneAPOEC1384666hearing impairment1CTD_human
TgeneAPOEC1527352Hepatic Form of Wilson Disease1CTD_human
TgeneAPOEC1565489Renal Insufficiency1CTD_human
TgeneAPOEC1704417Hyperlipoproteinemia Type IIb1CTD_human
TgeneAPOEC3495874Nonepileptic Seizures1CTD_human
TgeneAPOEC3658290Drug-Induced Acute Liver Injury1CTD_human
TgeneAPOEC3830362Early Pregnancy Loss1CTD_human
TgeneAPOEC4048158Convulsions1CTD_human
TgeneAPOEC4277682Chemical and Drug Induced Liver Injury1CTD_human
TgeneAPOEC4279912Chemically-Induced Liver Toxicity1CTD_human
TgeneAPOEC4316903Absence Seizures1CTD_human
TgeneAPOEC4317109Epileptic Seizures1CTD_human
TgeneAPOEC4317123Myoclonic Seizures1CTD_human
TgeneAPOEC4505436Generalized Absence Seizures1CTD_human
TgeneAPOEC4552766Miscarriage1CTD_human